VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: SoftBank Jumps as Asia Tech Tracks AI Rally
Value Add VC/Pulse/IPO

SoftBank Jumps as Asia Tech Tracks AI Rally

SoftBank shares surged more than 10% as Asian tech stocks tracked a strong Wall Street rally, with Arm's chip royalty optimism and gains at SK Hynix and Samsung all contributing.

TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
August 5, 2026
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

SoftBank shares jumped more than 10% as Asian tech stocks broadly tracked a Wall Street rally driven by strong corporate earnings and easing oil prices

2

Gains were reinforced by optimism specifically around Arm Holdings, SoftBank's majority-owned chip design subsidiary, on rising AI-related data center royalty and CPU development expectations

3

SK Hynix and Samsung both posted strong gains in the same session, underscoring how tightly Asian memory and chip stocks are now trading in sync with US AI infrastructure sentiment

4

It's a reminder that SoftBank's public valuation is now effectively a leveraged proxy for global AI infrastructure sentiment through Arm, not just a reflection of its own Vision Fund portfolio

TC

The VC Read · Trace's Take

Trace Cohen

SoftBank swinging double digits on Arm royalty sentiment alone, with no SoftBank-specific news, tells you how much leverage-to-AI-sentiment is now priced into that stock versus its actual Vision Fund fundamentals. It's a useful sentiment gauge, but a dangerous one to hold if you actually believe in SoftBank's underlying portfolio thesis rather than the Arm trade wrapped around it.

AI Valuations Tracker →

Analysis

SoftBank shares surged more than 10% this week as Asian technology stocks broadly tracked a strong overnight Wall Street rally fueled by solid corporate earnings and easing oil prices. The gains were reinforced by specific optimism around Arm Holdings, SoftBank's majority-owned chip design subsidiary, on rising expectations for AI-related data center royalty revenue and new CPU development plans.

The rally wasn't isolated to SoftBank. SK Hynix jumped nearly 7% and Samsung gained more than 4% in the same session, showing how tightly Asian memory and chip names are now trading in lockstep with US AI infrastructure sentiment -- when Wall Street rallies on AI optimism, the correlated move across Tokyo Electron, SK Hynix, Samsung and SoftBank tends to follow within the same trading session.

SoftBank's stock has become an increasingly volatile proxy for AI sentiment broadly, not just for its own Vision Fund portfolio performance -- shares have swung double digits in both directions multiple times this year purely on Arm-related royalty and chip-cycle optimism or pessimism, independent of any SoftBank-specific news. That makes it one of the more useful single-stock barometers for global AI infrastructure sentiment, precisely because its swings are driven by second-order exposure through Arm rather than direct operating results.

What to watch: whether Arm's actual royalty revenue disclosures in its next earnings report justify the optimism currently priced into SoftBank's stock, and whether the tight correlation between US AI sentiment and Asian chip-adjacent stocks continues to hold or starts to decouple as individual companies report differentiated results.

ShareXLinkedInEmail

More on

SK Hynix →SoftBank →

Reported by CNBC · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com